Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 24824548)

1.

Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.

Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE; Diabetes Prevention Program Research Group.

Diabetes Care. 2014 Aug;37(8):2253-60. doi: 10.2337/dc13-2471. Epub 2014 May 13.

PMID:
24824548
2.

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.

Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E; Diabetes Prevention Program Research Group.

Diabetes. 2005 May;54(5):1566-72.

3.

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group.

Diabetes. 2005 Aug;54(8):2404-14.

4.

Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.

Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R; Diabetes Prevention Program.

Diabetes. 2008 Apr;57(4):980-6. doi: 10.2337/db07-1419. Epub 2008 Jan 11.

5.

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

Ann Intern Med. 2005 Apr 19;142(8):611-9.

6.

Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.

Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9. doi: 10.1210/jc.2008-0772. Epub 2008 Sep 30.

7.

Alcohol consumption and diabetes risk in the Diabetes Prevention Program.

Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL; Diabetes Prevention Program Research Group.

Am J Clin Nutr. 2009 Sep;90(3):595-601. doi: 10.3945/ajcn.2008.27382. Epub 2009 Jul 29.

8.

Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E.

J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. doi: 10.1210/jc.2013-1452. Epub 2013 Aug 26.

9.

The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program.

Golden SH, Kim C, Barrett-Connor E, Nan B, Kong S, Goldberg R; Diabetes Prevention Program Research Group.

Metabolism. 2013 Sep;62(9):1313-22. doi: 10.1016/j.metabol.2013.04.005. Epub 2013 May 6.

10.

Early response to preventive strategies in the Diabetes Prevention Program.

Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, Marrero D, Brancati FL, Clark JM; Diabetes Prevention Program Research Group.

J Gen Intern Med. 2013 Dec;28(12):1629-36. doi: 10.1007/s11606-013-2548-4. Epub 2013 Jul 17.

11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM.

Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.

14.

Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.

Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, Marcovina SM, Montez M, Ratner RE, Saudek CD, Sherif H, Watson KE.

Diabet Med. 2013 Jan;30(1):46-55. doi: 10.1111/j.1464-5491.2012.03750.x.

15.

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.

Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D.

Diabetes Care. 2003 Jan;26(1):138-43.

PMID:
12502670
16.

Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group.

PLoS One. 2012;7(9):e44424. doi: 10.1371/journal.pone.0044424. Epub 2012 Sep 11.

17.

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.

Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM; Diabetes Prevention Program Research Group.

Diabetes Care. 2003 Jan;26(1):36-47.

18.

The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the diabetes prevention program outcomes study 10-year follow-up.

Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, Delahanty LM, Montez MG, Ackermann RT, Zhuo X, Knowler WC, Ratner RE; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2015 Apr;100(4):1646-53. doi: 10.1210/jc.2014-3761. Epub 2015 Feb 23.

PMID:
25706240
19.

HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.

Diabetes Prevention Program Research Group.

Diabetes Care. 2015 Jan;38(1):51-8. doi: 10.2337/dc14-0886. Epub 2014 Oct 21.

PMID:
25336746
20.

Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program.

Diabetes Prevention Program Research Group.

Diabetes Care. 2005 Oct;28(10):2472-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk